

FORM PTO-1440 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT
(Use several sheets if necessary)

Attorney Docket No.

014137-005840US

Serial No.:

08/349,177

Applicant: Howard M. Grey et al.

Filing Date: 12/2/94

Group: 1816

U.S. PATENT DOCUMENTS

Reference Designation

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
B1 A1	5,342,774	08/30/94	Boon et al.	435	240.2	12/12/91
B2 A2	5,200,320	04/06/93	Sette et al.	435	7.24	12/07/87
B3 A3	5,405,940	04/11/95	Boon et al.	530	328	08/31/92

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
B1	WO 94/05304 (PCT/US93/00157)	03/17/94	PCT WO	607K	7/06	
B2	WO 92/21033	11/26/92	PCT WO	-	-	yes
B3	WO 94/11738	3/26/94	PCT WO	-	-	
B4	WO 92/02543	2/92	PCT WO	-	-	

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Cells, E. et al., Proc. Nat'l. Acad. Sci. USA 91: 2105-2109 (March, 1994), "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes".
C2	Ding, M. et al., Biochem. Biophys. Res. Commun. 202(1): 549-555 (July 15, 1994), "Cloning and analysis of MAGE-1-related genes".
C3	Gaugler, B. et al., J. Exp. Med. 179(3): 921-930 (March 1, 1994), "Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes".
C4	Oakes, M.K. et al., Cancer Res. 54: 1627-1629 (April 1, 1994), "Molecular cytogenetic mapping of the human melanoma antigen (MAGE) gene family to chromosome region Xq27-qtr: implications for MAGE immunotherapy".
C5	Paul, W.F. (ed.), Fundamental Immunology, 3 rd ed., pp. 976-978 (1993), Raven Press, NY
C6	Traversari, C. et al., J. Exp. Med. 176: 1453-1457 (November, 1992), "A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E".
C7	Robbins Pathologic Basis of Disease, 4 th edition (R.S. Cotran et al., ed.), pp. 296-299 (1989), W.B. Saunders Co., Philadelphia
C8	Weynants, P. et al., Int. J. Cancer 56: 826-829 (1994), "Expression of MAGE genes by non-small-cell lung carcinomas".
C9	Zakut, R. et al., Cancer Res. 53: 5-8 (January 1, 1993), "Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines".

EXAMINER

R. Silman

DATE CONSIDERED

11/6/94

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

Attorney Docket No.

Serial No.:

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT
(Use several sheets if necessary)

014137-005840US

08/349,177

Applicant: Howard M. Grey et al.

Filing Date: 12/2/94

Group: 1816

C10 <i>AB3</i>	Urban, J.L., et al., "Autoimmune T Cells: Immune Recognition of Normal and Variant Peptide Epitopes and Peptide-Based Therapy," <i>Cell</i> 59:257-271 (October 20, 1989).
C11	Wraith, D.C., et al., "Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Mediated Immunotherapy," <i>Cell</i> 59:247-255 (October 20, 1989).
C12	Parker, K.C., et al., "Peptide Binding to HLA-A2 and HLA-B27 Isolated from <i>Escherichia coli</i> , <i>J. Biol. Chem.</i> 267(8):5451-5459 (March 15, 1992).
C13	Morrison, J., et al., "Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> , 22:903-907 (1992).
C14	Shimojo, N., et al., "Specificity of Peptide Binding by the HLA-A2.1 Molecule, <i>J. of Immunol.</i> 143(9):2939-2947 (November 1, 1989).
C15	Carreño, B.M., et al., "HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides," <i>Proc. Natl. Acad. Sci. USA</i> , 87:3420-3424 (May 1990).
C16	Henderson, R.A., et al., "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation," <i>Science</i> 255:1264-1266 (10 February 1992).
C17 <i>↓</i>	Kannagi, M., et al., "Target Epitope in the Tax Protein of Human T-Cell Leukemia Virus Type I Recognized by Class I Major Histocompatibility Complex-Restricted Cytotoxic T Cells," <i>J. of Virol.</i> 66(5):2928-2933 (May 1992).
C18	Falk, K., et al., " Allele-specific motifs revealed by sequencing of self-peptide eluted from MHC molecules, <i>Nature</i> 351:290-296 23 May 1991 .
C19 <i>AB3</i>	Jardetzky, T.S., et al., "Identification of self peptides bound to purified HLA-B27, <i>Nature</i> 353:326-329 (September 26, 1991).
C20	Hunt, D.F., et al., "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," <i>Science</i> 255:1261-1263 (March 6, 1992).
C21	Rotzschke, O., et al., "Naturally occurring peptide antigens derived from the MHC class-I-restricted processing pathway," <i>Immunology Today</i> 12(12):447-455 (1991).
C22	De Bruijn, M.L.H., et al., "Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses, <i>Eur. J. Immunol.</i> 21:2963-2970 (1991).
C23	Pamer, E.G., et al., "Precise prediction of a dominant class I MHC-restricted epitope of <i>Listeria monocytogenes</i> ," <i>Nature</i> 353:852-855 (October 31, 1991).
C24	DiBrino, M. et al., "Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides, <i>Proc. Nat'l. Acad. Sci. USA</i> 90: 1508-1512 (February 1993).
C25	Paul, W.F. (ed.), <i>Fundamental Immunology</i> , 2nd ed., pp. 473-487 (1989), Raven Press, NY
C26 <i>↓</i>	Romero et al., <i>J. Exp. Med.</i> 174: 603-612 (Sept. 1991), "H-2Kd-restricted antigenic peptides share a simple binding motif".

EXAMINER

N. S.

DATE CONSIDERED

11/6/98

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT
(Use several sheets if necessary)

014137-005840US

08/349,177

Applicant: Howard M. Grey et al.

Filing Date: 12/2/94

Group: 1816

<i>(D)</i> C27	Sette et al., Proc. Nat'l. Acad. Sci. USA 86: 3296-3300 (1989), "Prediction of major histocompatibility complex binding regions by sequence pattern analysis".
<i>(D)</i> C28	Krieger et al., J. Immunol. 146: 2331-2340 (1991) "Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition".
<i>(D)</i> C29	Sette et al., J. Immunol. 147: 3893-3900 (1991), "Random association between the peptide repertoire of A2.1 Class I and several different DR Class II molecules".
<i>(D)</i> C30	Knuth et al., Curr. Opinion Immunol. (1991) 3: 659-664, "Cellular and humoral immune responses against cancer: implications for cancer vaccines".
C31	Viret et al., Eur. J. Immunol. (1993) 23: 141-146, "Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes".
C32	Hayashi et al., J. Immunol. (1992) 149: 1223-1229, "Molecular cloning and characterization of the gene encoding mouse melanoma antigen by cDNA library transfection".
C33	Storkus et al., J. Immunol. (Oct. 1, 1993) 151: 3719-3727, "Identification of human melanoma peptides recognized by Class I restricted tumor infiltrating T lymphocytes".
C34	Slingluff et al., J. Immunol. (April 1, 1993) 150: 2955-2960, "Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes".
C35	Van der Bruggen et al., Science (Dec. 13, 1991) 254: 1643-1647, "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma".
C36	Maryanski et al., Cell 60: 63-72 (1990) "Competitor analogs for defined T cell antigens: peptides incorporating a putative binding motif and polyproline or polyglycine spacers"
C37	Bjorkman et al., "Structure of the human class I histocompatibility antigen HLA-A2," Nature (1987) 329: 506
C38	Buus et al., Science (1988) 242: 1045-1047 "Autologous peptides constitutively occupy the antigen binding site on Ia"
C39	Celis et al., Mol. Immunol. (1994) 31: 1423-1430, "Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles"
C40	Rammensee et al., Immunogenet. (1995) 41: 178-228, "MHC ligands and peptide motifs. first listing"
<i>(D)</i> C41	Rotzschke et al., Nature (Nov. 15, 1990) 348: 252-254, "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells"
C42	Rotzschke et al., Science (July 20, 1990) 249: 283-287, "Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y"
C43	Jiang et al., Science (May 22, 1992) 256: 1213-1215, "Role of CD8 ⁺ T cells in murine experimental allergic encephalomyelitis"

EXAMINER

U.S.

DATE CONSIDERED

11/6/94

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		Attorney Docket No.	Serial No.:
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		014137-005840US	08/349,177
Applicant: Howard M. Grey et al.			
		Filing Date: 12/2/94	Group: 1816
<i>PLA44</i>	Koh et al., <i>Science</i> (May 22, 1992) 256: 1210-1213, "Less mortality but more relapses in experimental allergic encephalomyelitis in CD8 ^{-/-} mice"		
C45	Miller et al., <i>Proc. Nat'l. Acad. Sci. USA</i> (January 1992) 89: 421-425, "Suppressor T cells generated by oral tolerization to myelin basic protein to suppress both <i>in vitro</i> and <i>in vivo</i> immune responses by the release of transforming growth factor β after antigen-specific triggering"		
C46	Foon, <i>Cancer Res.</i> (April 1, 1989) 49: 1621-1639, "Biological response modifiers: the new immunotherapy"		
C47	Parker et al., <i>J. Immunol.</i> (December 1, 1992) "Sequence motifs important for peptide binding to the human MHC Class I molecule, HLA-A2"		

c:\work\14137\005840us\cy005840-1449.doc

EXAMINER

DATE CONSIDERED

11/16/94

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

FORM PTO-1449 (Modified)

Attorney Docket No.
14137-0058-40

Serial No.:
08/349,177

AUG 28 1997

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT
(Use several sheets if necessary)

AUG 4 1997

Applicant: HAROLD M. GREY, et al.

GROUP 1800

Filing Date:
December 2, 1994

Group: 1816

Reference Designation

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

C48 RBS	Sarobe et al., Eur. J. Immunol. (1991) 21: 1555-1558 "Induction of antibodies against a peptide haptene does not require covalent linkage between the haptene and a class II presentable T helper peptide"

EXAMINER

R. Silver

DATE CONSIDERED

10/6/98

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.